FDA extends shelf life of COVID-19 treatment for hospitalized adults
The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults. The six-month extension applies to all retained product held in accordance with storage conditions detailed in the fact sheet for health care providers.
Related News Articles
Headline
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…
News
To enjoy a healthy Thanksgiving with family and friends, get vaccinated against the flu and COVID-19. That’s the message of AHA’s latest United Against the Flu…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical…